MedInCell Stock Rises 5.72% This Morning, Approaching a Key Technical Threshold
The stock of the biotech company from Montpellier is among the top gainers in today's session, Wednesday, April 8, driven by a general momentum in the Paris market. At 10:30 AM, MedInCell is trading at 22.92 euros, up 5.72% from yesterday's close, amid a significant rebound of the CAC 40.
MedInCell's stock is regaining ground this morning after a challenging quarter: the stock is still down 10.82% over three months, despite an impressive annual performance of 75.5%. The share price, which was around 21.68 euros at yesterday's close, benefits today from the general momentum on European markets. The CAC 40 is up 3.97% at 8,222.85 points, while the SBF 120 is up 3.92%. This upward trend coincides with the announcement of a ceasefire between the United States and Iran, a major geopolitical event that boosts the entire Paris stock market. The pharmaceutical sector also enjoys a favorable tone, with Sanofi up 0.37% and UCB up 0.95%, although these changes are very modest compared to MedInCell's.
On the financial calendar, the next milestone is the publication of the annual results for the fiscal year 2025-2026, expected on June 16. The general meeting is scheduled for September 10, 2026.
Technical Analysis Suggests Close Watch
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical analysis perspective, this morning's movement brings the share price close to watch zones. At a level of 22.92 euros, the stock is now at 86% of the upper Bollinger band (23.42 euros), a configuration that signals a potential overbought zone. The lower bound, at 19.85 euros, remains distant, reflecting a sharp recovery of the stock within the volatility channel.
The RSI, at 44, is still in neutral territory, far from the overheating thresholds usually set beyond 70. This relative strength indicator shows that, despite today's rebound, the bullish momentum has not yet reached an excessive level. Moreover, the price remains below its 50-day moving average (23.08 euros) and its 200-day moving average (23.55 euros): crossing these thresholds would constitute a significant technical signal for the future. The identified support is at 20.24 euros, while the nearest resistance is at 24.94 euros.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
